AT-RvD1 combined with DEX is highly effective in treating TNF-α-mediated disruption of the salivary gland epithelium. [electronic resource]
Producer: 20171026ISSN:- 2051-817X
- Animals
- Anti-Inflammatory Agents, Non-Steroidal -- administration & dosage
- Aspirin -- administration & dosage
- Combined Modality Therapy -- methods
- Dexamethasone -- administration & dosage
- Docosahexaenoic Acids -- administration & dosage
- Glucocorticoids -- administration & dosage
- Inflammation -- metabolism
- Rats
- Receptors, Lipoxin -- drug effects
- Salivary Glands -- cytology
- Signal Transduction -- physiology
- Sjogren's Syndrome -- drug therapy
- Tumor Necrosis Factor-alpha -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.